|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
GBD 2015 Disease and Injury Incidence and
Prevalence Collaborators, . Global, regional, and national
incidence, prevalence, and years lived with disability for 310
diseases and injuries, 1990–2015: A systematic analysis for the
global burden of disease study 2015. Lancet. 388:1545–1602. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fakih MG: Metastatic colorectal cancer:
Current state and future directions. J Clin Oncol. 33:1809–1824.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boland P and Ma W: Immunotherapy for
colorectal cancer. Cancers (Basel). 9(pii): E502017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jeffery M, Hickey BE, Hider PN and See AM:
Follow-up strategies for patients treated for non-metastatic
colorectal cancer. Cochrane Database Syst Rev.
11:CD0022002016.PubMed/NCBI
|
|
7
|
Shigeta K, Ishii Y, Hasegawa H, Okabayashi
K and Kitagawa Y: Clinical usefulness of 5-FU metabolic enzymes as
predictive markers of response to chemotherapy in colorectal
cancer. World J Surg. 40:1019–1020. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sobrero A, Guglielmi A, Grossi F, Puglisi
F and Aschele C: Mechanism of action of fluoropyrimidines:
relevance to the new developments in colorectal cancer
chemotherapy. Semin Oncol. 27 (5 Suppl 10):S72–S77. 2000.
|
|
9
|
Iqbal A and George TJ: Randomized clinical
trials in colon and rectal cancer. Surg Oncol Clin N Am.
26:689–704. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma L, Wen S, Zhan Y, He Y, Liu X and Jiang
J: Anticancer effects of the Chinese medicine matrine on murine
hepatocellular carcinoma cells. Planta Med. 74:245–251. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang W, You RL, Qin WJ, Hai LN, Fang MJ,
Huang GH, Kang RX, Li MH, Qiao YF, Li JW and Li AP: Anti-tumor
activities of active ingredients in compound kushen injection. Acta
Pharmacol Sin. 36:676–679. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou YJ, Guo YJ, Yang XL and Ou ZL:
Anti-cervical cancer role of matrine, oxymatrine and Sophora
Flavescens alkaloid gels and its mechanism. J Cancer.
9:1357–1364. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nourmohammadi S, Aung TN, Cui J, Pei JV,
De Ieso ML, Harata-Lee Y, Qu Z, Adelson DL and Yool AJ: Effect of
compound kushen injection, a natural compound mixture, and its
identified chemical components on migration and invasion of colon,
brain, and breast cancer cell lines. Front Oncol. 9:3142019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang L and Huang J: Oxymatrine inhibits
epithelial-mesenchymal transition through regulation of NF-κB
signaling in colorectal cancer cells. Oncol Rep. 36:1333–1338.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Joshi P, Vishwakarma RA and Bharate SB:
Natural alkaloids as P-gp inhibitors for multidrug resistance
reversal in cancer. Eur J Med Chem. 138:273–292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mitra A, Mishra L and Li S: EMT, CTCs and
CSCs in tumor relapse and drug-resistance. Oncotarget.
6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21(pii): E9652016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: Mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
19
|
Smith BN and Bhowmick NA: Role of EMT in
metastasis and therapy resistance. J Clin Med. 5(pii): E172016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ye X and Weinberg RA:
Epithelial-mesenchymal plasticity: A central regulator of cancer
progression. Trends Cell Biol. 25:675–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bao Y, Lu Y, Wang X, Feng W, Sun X, Guo H,
Tang C, Zhang X, Shi Q and Yu H: Eukaryotic translation initiation
factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer
through epithelial mesenchymal transition. Cancer Cell Int.
15:1092015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou Z, Zhang L, Xie B, Wang X, Yang X,
Ding N, Zhang J, Liu Q, Tan G, Feng D and Sun LQ: FOXC2 promotes
chemoresistance in nasopharyngeal carcinomas via induction of
epithelial mesenchymal transition. Cancer Lett. 363:137–145. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma JL, Zeng S, Zhang Y, Deng GL and Shen
H: Epithelial-mesenchymal transition plays a critical role in drug
resistance of hepatocellular carcinoma cells to oxaliplatin. Tumour
Biol. 37:6177–6184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X,
Chen S, Chen C and Wang Z: Acquisition of epithelial-mesenchymal
transition is associated with Skp2 expression in
paclitaxel-resistant breast cancer cells. Br J Cancer.
110:1958–1967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arias AM: Epithelial mesenchymal
interactions in cancer and development. Cell. 105:425–431. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mayo MW and Baldwin AS: The transcription
factor NF-kappaB: Control of oncogenesis and cancer therapy
resistance. Biochim Biophys Acta. 1470:M55–M62. 2000.PubMed/NCBI
|
|
29
|
Li M, Su BS, Chang LH, Gao Q, Chen KL, An
P, Huang C, Yang J and Li ZF: Oxymatrine induces apoptosis in human
cervical cancer cells through guanine nucleotide depletion.
Anticancer Drugs. 25:161–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang B, Han Q and Zhu Y: Oxymatrine
inhibited cell proliferation by inducing apoptosis in human lung
cancer A549 cells. Biomed Mater Eng. 26 (Suppl 1):S165–S172.
2015.PubMed/NCBI
|
|
31
|
Liu Y, Bi T, Dai W, Wang G, Qian L, Gao Q
and Shen G: Effects of oxymatrine on the proliferation and
apoptosis of human hepatoma carcinoma cells. Technol Cancer Res
Treat. 15:487–497. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Jiang K and Zhao F: Oxymatrine
suppresses proliferation and facilitates apoptosis of human ovarian
cancer cells through upregulating microRNA-29b and downregulating
matrix metalloproteinase-2 expression. Mol Med Rep. 12:5369–5374.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo SX, Deng WY, Wang XF, Lü HF, Han LL,
Chen BB, Chen XB and Li N: Molecular mechanism of
indirubin-3′-monoxime and Matrine in the reversal of paclitaxel
resistance in NCI-H520/TAX25 cell line. Chin Med J (Engl).
126:925–929. 2013.PubMed/NCBI
|
|
34
|
Wang HQ, Jin JJ and Wang J: Matrine
induces mitochondrial apoptosis in cisplatin-resistant non-small
cell lung cancer cells via suppression of β-catenin/survivin
signaling. Oncol Rep. 33:2561–2566. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tse JC and Kalluri R: Mechanisms of
metastasis: Epithelial-to-mesenchymal transition and contribution
of tumor microenvironment. J Cell Biochem. 101:816–829. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kong D, Li Y, Wang Z and Sarkar FH: Cancer
stem cells and epithelial-to-mesenchymal transition
(EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel).
3:716–729. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kaltschmidt B, Greiner JFW, Kadhim HM and
Kaltschmidt C: Subunit-specific role of NF-κB in cancer.
Biomedicines. 6(pii): E442018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang S, Liu Z, Wang L and Zhang X:
NF-kappaB signaling pathway, inflammation and colorectal cancer.
Cell Mol Immunol. 6:327–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Maier HJ, Schmidt-Strassburger U, Huber
MA, Wiedemann EM, Beug H and Wirth T: NF-kappaB promotes
epithelial-mesenchymal transition, migration and invasion of
pancreatic carcinoma cells. Cancer Lett. 295:214–228. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu Y and Zhou BP:
TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and
invasion. Br J Cancer. 102:639–644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao C, Zhao Q, Zhang C, Wang G, Yao Y,
Huang X, Zhan F, Zhu Y, Shi J, Chen J, et al: miR-15b-5p
resensitizes colon cancer cells to 5-fluorouracil by promoting
apoptosis via the NF-κB/XIAP axis. Sci Rep. 7:41942017. View Article : Google Scholar : PubMed/NCBI
|
